Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV



Status:Recruiting
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:August 2015
End Date:December 2016
Contact:Tracy Wolbach
Email:TracyWolbach@westat.com
Phone:240-453-2658

Use our guide to learn which trials are right for you!

A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1

This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of
ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.

This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of
ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.
Patients must have been treated with HAART for at least 6 months and be failing or have
recently failed (i.e., in the last 8 weeks) therapy to determine baseline viral load.

Days 0-6 of the study will be a "control period." During Days 0 through 6 patients will be
monitored on current failing therapy (or no therapy, if the patient has failed and
discontinued treatment within the 8 weeks preceding Screening).

Days 7-13 of the study will be an "essential monotherapy period." During Days 7 through 13
patients will continue on current failing therapy and receive one 2000 mg dose (loading
dose) of ibalizumab on Day 7. Day 7 is Baseline for the treatment period (Day 7-Week 25).

Day 14-Week 25 of the study will be the "maintenance period." On Day 14 (primary endpoint),
the OBR will be initiated and must include at least one agent to which the patient's virus
is susceptible. Beginning at Day 21, 800 mg of ibalizumab will be administered every 2 weeks
through Week 23.

End of Study evaluations will be performed at Week 25, and a follow-up visit will be
conducted at Week 29.

Inclusion Criteria:

- Are capable of understanding and have voluntarily signed the informed consent
document

- Have documented HIV-1 infection by official, signed, written history (e.g.,
laboratory report), otherwise an HIV-antibody test will be performed

- Have no acquired immunodeficiency syndrome (AIDS)-defining events in the 3 months
before Screening, other than cutaneous Kaposi's sarcoma or wasting syndrome due to
HIV

- Are able and willing to comply with all protocol requirements and procedures

- Have a life expectancy that is >6 months.

- Have a viral load >1,000 copies/mL and documented resistance to at least one
antiretroviral medication from each of three classes of antiretroviral medications as
measured by resistance testing

- Have a history of at least 6 months on antiretroviral treatment

- Are receiving a stable highly active antiretroviral regimen for at least 8 weeks
before Screening and are willing to continue that regimen until Day 14, OR (in the
past 8 weeks) have failed and are off therapy and are willing to stay off therapy
until Day 14

- Have full viral sensitivity/susceptibility to at least one antiretroviral agent,
other than ibalizumab, as determined by the screening resistance tests and be willing
and able to be treated with at least one agent to which the patient's viral isolate
is fully sensitive/susceptible according to the screening resistance tests as a
component of OBR

- If sexually active, are willing to use an effective method of contraception during
the study and for 30 days after the last administration of the study drug

Exclusion Criteria:

- Any active AIDS-defining illness per Category C conditions according to the Centers
for Disease Control and Prevention (CDC) Classification System for HIV Infection,
with the following exceptions: cutaneous Kaposi's sarcoma and wasting syndrome due to
HIV

- Any significant diseases (other than HIV-1 infection) or clinically significant
findings, including psychiatric and behavioral problems, determined from screening,
medical history and/or physical examination that, in the investigator's opinion,
would preclude the patient from participating in this study

- Any significant acute illness within 1 week before the initial administration of
study drug

- Any active infection secondary to HIV requiring acute therapy; however, patients that
require maintenance therapy (i.e., secondary prophylaxis for opportunistic
infections) will be eligible for the study.

- Any immunomodulating therapy (including interferon), systemic steroids, or systemic
chemotherapy within 12 weeks before Enrollment

- Any prior exposure to ibalizumab (formerly TNX-355 and Hu5A8)

- Any vaccination within 7 days before Enrollment

- Any female patient who either is pregnant, intends to become pregnant, or is
currently breastfeeding

- Any current alcohol or illicit drug use that, in the investigator's opinion, will
interfere with the patient's ability to comply with the study schedule and protocol
evaluations

- Any previous clinically significant allergy or hypersensitivity to any excipient in
the ibalizumab formulation

- Any radiation therapy during the 28 days before first administration of
investigational medication

- Any Grade 3 or 4 laboratory abnormality according to the Division of AIDS grading
scale, except for the following asymptomatic Grade 3 events triglyceride elevation
total cholesterol elevation
We found this trial at
29
sites
Baltimore, Maryland 21201
Principal Investigator: Bruce Gilliam, MD
Phone: 410-706-0100
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
900 East 30th Street
Austin, Texas 78705
512-480-9660
?
mi
from
Austin, TX
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Principal Investigator: Robert Grossberg, MD
Phone: 718-920-5276
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Miami, Florida 33124
(305) 284-2211
Principal Investigator: Hector Bolivar, MD
Phone: 305-243-5621
University of Miami A private research university with more than 15,000 students from around the...
?
mi
from
Miami, FL
Click here to add this to my saved trials
Atlanta, Georgia 30308
Principal Investigator: Melanie Thompson, MD
Phone: 404-276-7720
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Charlotte, North Carolina 28203
Principal Investigator: Marc Johnson, MD
Phone: 704-355-0244
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Louis Sloan, MD
Phone: 214-276-5618
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48202
Principal Investigator: Norman Markowitz, MD
Phone: 313-916-2570
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Fort Lauderdale, Florida 33316
Principal Investigator: Gary Richmond, MD
Phone: 954-524-2250
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Fort Pierce, Florida 34982
Principal Investigator: Moti Ramgopal, MD
Phone: 772-464-9746
?
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
Houston, Texas 77098
Principal Investigator: Shannon Schrader, MD
Phone: 713-526-7732
?
mi
from
Houston, TX
Click here to add this to my saved trials
Long Beach, California 90813
Principal Investigator: Jerome DeVente, MD
Phone: 562-624-4943
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Los Angeles, California 90008
Principal Investigator: William King, MD
Phone: 323-617-5409
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90027
Principal Investigator: William Towner, MD
Phone: 323-783-8172
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90036
Principal Investigator: Michael Gottlieb, MD
Phone: 323-954-0400
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90059
Principal Investigator: Wilbert Jordan
Phone: 323-568-3359
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90069
Principal Investigator: Tony Mills, MD
Phone: 310-550-2271
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90028
Principal Investigator: Laveeza Bhatti, MD
Phone: 323-913-1033
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Michael Kozal, MD
Phone: 203-737-4040
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New York, New York 10018
Principal Investigator: Jerome Ernst, MD
Phone: 212-924-3934
?
mi
from
New York, NY
Click here to add this to my saved trials
Norwalk, Connecticut 06851
Principal Investigator: Gary Blick, MD
Phone: 203-852-9525
?
mi
from
Norwalk, CT
Click here to add this to my saved trials
1701 North Mills Avenue
Orlando, Florida 32803
(407)647-3960
Principal Investigator: Edwin DeJesus, MD
Phone: 407-409-7125
Orlando Immunology Center Orlando Immunology Center , or simply (OIC) is a part of Infectious...
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Palm Springs, California 92262
Principal Investigator: Richard Loftus, MD
Phone: 760-778-7799
?
mi
from
Palm Springs, CA
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: Jacob Lalezari, MD
Phone: 415-353-0800
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Francisco, California 94118
Principal Investigator: Jeffrey Fessel, MD
Phone: 415-933-3487
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Juan, 00909
Principal Investigator: Javier Morales, MD
Phone: 787-723-5945
?
mi
from
San Juan,
Click here to add this to my saved trials
Southfield, Michigan 48075
Principal Investigator: Rodger MacArthur, MD
Phone: 248-552-0620
?
mi
from
Southfield, MI
Click here to add this to my saved trials
Washington, District of Columbia 20057
Principal Investigator: Princy Kumar, MD
Phone: 202-444-0371
?
mi
from
Washington,
Click here to add this to my saved trials
West Palm Beach, Florida 33401
Principal Investigator: Olayemi Osiyemi, MD
Phone: 561-855-7871
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials